By Sabela Ojea

 

AstraZeneca PLC said Thursday that its Lynparza drug has been approved in China to treat advanced prostate cancer.

The pharmaceutical giant said the approval by China's National Medical Products Administration was based on a subgroup analysis of the profound phase 3 trial.

 

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

 

(END) Dow Jones Newswires

June 24, 2021 02:23 ET (06:23 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Jun 2021 to Jul 2021 Click Here for more AstraZeneca Charts.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Jul 2020 to Jul 2021 Click Here for more AstraZeneca Charts.